C1 esterase inhibitor (human) - Biologic Drug Details

Summary for c1 esterase inhibitor (human)

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2

Pharmacology for c1 esterase inhibitor (human)

Mechanism of Action	Kallikrein Inhibitors
Physiological Effect	Decreased Vascular Permeability
Established Pharmacologic Class	Human C1 Esterase Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for c1 esterase inhibitor (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for c1 esterase inhibitor (human) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	CINRYZE	c1 esterase inhibitor (human)	For Injection	125267		2037-12-11	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	CINRYZE	c1 esterase inhibitor (human)	For Injection	125267		2035-09-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for c1 esterase inhibitor (human) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	CINRYZE	c1 esterase inhibitor (human)	For Injection	125267		2038-02-28	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	CINRYZE	c1 esterase inhibitor (human)	For Injection	125267		2039-03-19	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	CINRYZE	c1 esterase inhibitor (human)	For Injection	125267		2039-03-05	Patent claims search

International Patents for c1 esterase inhibitor (human)

Country	Patent Number	Estimated Expiration
Montenegro	02865
Mexico	373965
Japan	2021088599

Market Dynamics and Financial Trajectory for C1 Esterase Inhibitor (Human)

Last updated: February 14, 2026

Market Overview

C1 esterase inhibitor (human) primarily treats hereditary angioedema (HAE), a rare genetic disorder characterized by unpredictable, recurrent swelling episodes. The drug is marketed under multiple brand names, with Haegarda (Shire/BIONOVIA) and Berinert (CSL Behring) being the most prominent.

Market Size and Growth

• The global HAE treatment market was valued at approximately $1.8 billion in 2022.
• Expected compound annual growth rate (CAGR) from 2023 to 2030 stands at 8-10%.
• The growth hinges on increasing HAE diagnosis rates, the launch of new therapies, and expanding global access.

Market Drivers

1. Rising Diagnosis and Awareness
   Diagnosis rates remain low, but increased awareness enhances detection. Over 7,000 HAE cases are estimated worldwide, with the majority undiagnosed.

2. Expanding Geographic Access
   Developed markets (U.S., Europe) exhibit high penetration, but emerging markets (Asia-Pacific, Latin America) receive accelerated access via partnerships and regulatory pathways.

3. Product Approvals and Label Expansion
   The approval of subcutaneous formulations like Haegarda and berinert's new indications enhances treatment flexibility, supporting market growth.

4. Biologic Excellence & Portfolio Expansion
   The dominance of plasma-derived C1 esterase inhibitors faces competition from recombinant alternatives, pushing innovation.

Competitive Landscape

• CSL Behring: Berinert (plasma-derived), with over $1.2 billion annual revenue.
• BioCryst Pharmaceuticals: Orladeyo (small molecule bradykinin B2 receptor antagonist) entering the space.
• Kalvista (Kadimastat): Oral inhibitors in development.
• Ruconest (Phycoerythrin): Recombinant C1 esterase inhibitor, gaining market share in Europe.

Financial Trajectories

• Revenue Growth Trends
  Berinert revenues are growing at 3-5% annually, driven by increased usage and geographic expansion. Haegarda shows double-digit growth (around 10-12% CAGR) benefiting from subcutaneous convenience.

• R&D Investments
  Major players invest $100-200 million annually in pipeline development, including gene therapies and recombinant C1 inhibitors.

• Pricing Dynamics
  Pricing ranges from $20,000 to $40,000 per treatment course. Price increases are limited by payer negotiations but supported by clinical benefits over older therapies.

• Profitability
  The plasma-derived sector maintains high margins (above 50% gross margin), though pressures emerge from biosimilar competition and cost containment measures.

Regulatory and Policy Impact

• The FDA approved Haegarda as a prophylactic agent in 2017, expanding the treatment protocol.
• The European Medicines Agency (EMA) approved Haegarda in 2018.
• Reimbursement policies favor newer subcutaneous formulations; hospital vs. outpatient settings affect revenue streams.

Pipeline and Future Outlook

• Recombinant C1 esterase inhibitors and gene therapies, such as ATN-102 and VY-AER-01, aim to reduce dependence on plasma-derived products.
• Market entry of gene therapies could disrupt current revenue streams within 5-7 years if clinical success is achieved.
• Patent expirations for key formulations are expected post-2030, pressuring pricing but also opening opportunities for biosimilars.

Conclusion

The biologic C1 esterase inhibitor market exhibits steady growth, supported by increased diagnosis, improved formulations, and expanding geographic access. Revenue streams are characterized by high margins but face competitive and regulatory pressures. Anticipated innovations in recombinant and gene therapies may redefine the landscape over the next decade.

---

Key Takeaways

• The global market for C1 esterase inhibitor (human) treatment was valued at approximately $1.8 billion in 2022 with an expected CAGR of 8-10%.
• Major revenues derive from plasma-derived products like Berinert, with newer formulations and recombinant options gaining traction.
• Growth drivers include increased diagnosis, geographic expansion, and formulation innovation.
• Prices range from $20,000 to $40,000 per treatment course, with high profit margins supported by clinical efficacy.
• Pipeline developments in recombinant and gene therapies threaten to disrupt current revenue models within the next decade.

---

FAQs

1. What factors most influence market growth for C1 esterase inhibitors?
   Diagnosis rates, geographic expansion, new formulation approvals, and pipeline innovations.

2. How does competition impact pricing in this market?
   Biosimilars and recombinant products exert downward pressure, while value-based pricing based on clinical outcomes remains a trend.

3. What are the key regulatory considerations?
   Approvals in emerging markets and policy shifts toward outpatient settings influence revenue potential.

4. When might gene therapies significantly impact the market?
   Within 5-7 years, if ongoing clinical trials for gene therapies succeed and gain regulatory approval.

5. What is the outlook for biosimilar entrants?
   Biosimilar versions of plasma-derived C1 esterase inhibitors are expected post-2030, potentially reducing prices and margins.

---

Sources

[1] MarketWatch. "Hereditary Angioedema Treatment Market Size, Share & Trends," 2023.
[2] GlobalData. "Hereditary Angioedema Market Outlook," 2023.
[3] CSL Behring Financial Reports, 2022.
[4] BIOCENTURY. "Pipeline Review - Biologic C1 Esterase Inhibitors," 2023.